AKD Global announces new class of cancer treatments in development

Jan 22 2010

AKD Global announced today the discovery of a new class of cancer treatments in development, providing hope for millions of sufferers. The spectacular results demonstrate a highly potent effect on cancer cells with no toxicity to healthy tissue. AKD is raising funds to continue development.

“The results are spectacular and with the right support we may be in a position to rewrite the history books for this disease. We are now working to raise additional funding to expedite bringing this therapy to market.”

Currently, cancer sufferers who are non-responsive to chemotherapy and radiation therapy have limited therapeutic options. Treatments are aggressive and associated with ‘side effects’ which may be as detrimental as the disease.

“We have discovered and patented a revolutionary new class of anti-cancer agents that may eliminate the need for these approaches and change the lives of many cancer patients,” said Dennis Wright, lead scientist on the project. Early in-vitro data has been successful and animal testing in mice has shown no adverse effects with oral administration at concentrations thousands of times higher than used in our in-vitro testing.

The goal for cancer research is to find the cure for cancer. AKD Global’s president, Chris Henshall, explains that, “The results are spectacular and with the right support we may be in a position to rewrite the history books for this disease. We are now working to raise additional funding to expedite bringing this therapy to market.”

This is a new chemical entity (NCE) with reproducible evidence of antineoplastic and antibiotic activity.

The mechanism of action is consistent with apoptotic pathway activation and simply shuts down the malignancy (cancer cells showing exponential increase in Caspase 3 levels) after exposure to our molecules.

The animal model in mice shows no evidence of toxicity.

Our antineoplastic has been tested against cell lines (U87, HEP G2) that are among the most difficult cancers to treat. Further testing may show that our molecules also have therapeutic utility for additional cancer types (e.g. breast cancer, prostate cancer, blastomas, carcinomas, lymphomas, sarcomas).

SOURCE AKD Global, LLC